5-Alpha Reductase Deficiency Market Report 2025

The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to research and development, regulatory landscape, healthcare infrastructure, increased awareness and education, health insurance coverage.

The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to innovations in therapeutics, genetic research advances, precision medicine, global health initiatives, integration of gene therapies. Major trends in the forecast period include advancements in treatment options, diagnostic innovations, patient-centric approaches, regulatory landscape, market access and affordability.

The escalating number of research and development endeavors in genomics is significantly contributing to the growth trajectory of the 5-alpha reductase deficiency market. Genomics, involving the comprehensive study of an individual's entire genome, including the interplay between genes and their environment, serves as a pivotal tool in diagnosing 5-alpha reductase deficiency by pinpointing specific genetic mutations responsible for the condition. Consequently, the surge in research and development activities within genomics is poised to play a crucial role in not only uncovering but also treating this disorder. As detailed in the 'Accelerating Access to Genomics for Global Health' report by the World Health Organization (WHO) in July 2022, the percentage of nations equipped to perform genomic surveillance surged from 54% to 68% between March 2021 and January 2022. Therefore, the burgeoning research and development efforts in genomics are forecasted to be a primary driver propelling the 5-alpha reductase deficiency market.

The mounting prevalence of genetic and rare diseases stands poised to propel the growth trajectory of the 5-alpha reductase deficiency market in the forthcoming years. Genetic and rare diseases, arising from alterations in an individual's genes and being uncommon within the general populace, highlight the intricate role of genetic factors in human development, especially concerning sexual differentiation, exemplified by 5-alpha reductase deficiency. As noted in November 2022 by the Australian Government Department of Health, approximately 7,000 rare illnesses, either fatal or severely disabling, exist. These rare diseases impact about 8% of Australians, totaling around 2 million individuals, with roughly 80% being genetic in nature. Consequently, the escalating prevalence of genetic and rare diseases constitutes a pivotal factor propelling the 5-alpha reductase deficiency market.

The emergence of innovative genetic testing methodologies for diagnosing rare diseases constitutes a key trend in the 5-alpha reductase deficiency market. Leading entities operating within this domain are directing their efforts toward developing pioneering genetic testing solutions that efficiently diagnose rare conditions such as 5-alpha reductase deficiency, particularly in their nascent stages. These advancements in diagnostics not only offer a competitive advantage to major market players but also enhance their position in the market. For instance, in June 2022, Avesthagen Limited, a US-based integrated systems biology platform company, unveiled its latest genetic testing portfolio. The genome panels encompassed in this portfolio present highly specialized, disease-centric analyses tailored for rare genetic diseases, thereby showcasing significant strides in the diagnostic landscape.

Leading companies in the 5-alpha reductase deficiency market are focusing on the development of advanced products, such as consumer-initiated genetic tests, enabling individuals to access personal genetic information privately and directly, without requiring a healthcare provider's referral. A consumer-initiated genetic test allows individuals to order genetic testing from a laboratory or testing company independently, providing insights into genetic predispositions, ancestry, or health-related traits without the need for a healthcare provider's involvement. For example, in July 2023, Quest Diagnostics, a US-based diagnostic information services provider, introduced Genetic Insights, a consumer-initiated genetic test. This new product helps individuals evaluate their risk of developing certain hereditary health conditions. It offers advanced technology, personalized health reports, and access to genetic counseling. By analyzing a saliva sample, Genetic Insights assesses 36 genes to identify risks for nearly two dozen hereditary conditions, including breast and colon cancer, heart and blood disorders, and carrier status for conditions such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test is designed to address gaps in existing consumer genetic tests and utilizes state-of-the-art next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person's genome compared to traditional microarray testing.

In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical firm, completed the acquisition of ENTADFI (finasteride/tadalafil) from Veru Inc. for an approximate sum of $100 million. This acquisition significantly expands the company's scope across various pharmaceutical sectors. By acquiring ENTADFI, Blue Water gains entry into the commercial domain while also mitigating expenditure and securing crucial revenue streams for the vaccine candidate pipeline. Despite this expansion, Blue Water remains steadfast in its primary mission of aiding individuals in need and is eager to enhance this asset and the pipeline for patients worldwide. Veru Inc. functions as a US-based biopharmaceutical company.

Major companies operating in the 5-alpha reductase deficiency market include F. Hoffmann-La Roche Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Alma Lasers Ltd., Viveve Medical Inc., Fotona d.o.o, Almirall SA, Hologic Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Roivant Sciences Ltd., Sanofi Genzyme, Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zoetis Inc., Cadila Healthcare Limited, Endo International plc.

North America was the largest region in the 5-alpha reductase deficiency market in 2024. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

5-alpha reductase deficiency is a disorder that impacts male sexual development, both preceding and during puberty. Individuals with this condition experience insufficient production of dihydrotestosterone, a crucial hormone for male sexual development.

The primary diagnostic methods for 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, and genetic screening, among others. Chromosome analysis is employed to determine the patient's chromosomal makeup, distinguishing between XX (Female) and XY (Male) chromosomes. Various treatments are available for 5-alpha reductase deficiency, including surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and other interventions. End-users of these treatments include hospitals, specialty clinics, and other medical facilities.

The 5-alpha reductase deficiency market research report is one of a series of new reports that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The 5-alpha reductase deficiency market includes revenues earned by entities by providing ultrasound screening diagnosis and surgical procedures to treat 5-alpha reductase deficiencies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.